Skip to main content
. Author manuscript; available in PMC: 2015 Sep 1.
Published in final edited form as: Inflamm Res. 2014 May 30;63(9):703–710. doi: 10.1007/s00011-014-0743-3

Figure 3. Inhibition of p38 MAPK has a minor effect on biglycan-induced ICAM-1 and MCP-1 production in human AVICs.

Figure 3

A. Representative immunoblots show that biglycan (BGN, 0.10 μg/mL) induced rapid phosphorylation of p38 MAPK. B. Inhibition of p38 MAPK with SB203580 (5, 10 and 20 μmol/L) resulted in a minimal reduction in ICAM-1 and MCP-1 production following biglycan stimulation. Values are means ± SE. n = 3; *P<0.05 vs. untreated control.